过去十年，随着有关前列腺特异性膜抗原 (PSMA) PET/CT 诊断准确性及其对患者管理影响的大量数据的发布，人们对前列腺特异性膜抗原 (PSMA) PET/CT 在前列腺癌诊断中的重要性的认识不断提高。最近，我国正在进行多项有关 PSMA PET/CT 的临床试验和研究，预计这项检查在未来将变得越来越普遍。本综述解释了 PSMA PET/CT 的特点、其诊断能力以及相对于其他方式的优越性、提出的三项 PSMA PET/CT 解释标准（欧洲核医学协会 [EANM]、前列腺癌分子影像标准化评估 [PROMISE] ，以及 PSMA 报告和数据系统 [PSMA-RADS]），以及 PSMA PET/CT 在前列腺癌治疗中的应用（改善局部控制、寡转移照射和挽救性放射治疗），结合实际临床图像和最新发现.© 2024。作者。

Recognition of the importance of prostate-specific membrane antigen (PSMA) PET/CT in the diagnosis of prostate cancer has steadily increased following the publication of extensive data on its diagnostic accuracy and impact on patient management over the past decade. Several recent clinical trials and investigations regarding PSMA PET/CT have been ongoing in our country, and this examination is expected to become increasingly widespread in the future. This review explains the characteristics of PSMA PET/CT, its diagnostic capabilities and superiority over other modalities, the three proposed PSMA PET/CT interpretation criteria (the European Association of Nuclear Medicine [EANM], the Prostate Cancer Molecular Imaging Standardized Evaluation [PROMISE], and the PSMA Reporting and Data System [PSMA-RADS]), and the application of PSMA PET/CT to prostate cancer treatment (improvement of local control, irradiation of oligometastases, and salvage radiotherapy), incorporating actual clinical images and the latest findings.© 2024. The Author(s).